Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 22,850 | 21,607 | 28,787 | 53,076 | 89,018 |
| TOTAL | $23,576 | $22,521 | $30,154 | $56,584 | $92,417 |
| Non-Current Assets | |||||
| PPE Net | 82 | 88 | 2 | 24 | 39 |
| Other Non-Current Assets | 322 | 41 | 0 | 215 | 350 |
| TOTAL | $403 | $129 | $2 | $239 | $389 |
| Total Assets | $23,980 | $22,650 | $30,156 | $56,824 | $92,805 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,352 | 1,670 | 843 | 1,773 | 4,504 |
| Accrued Expenses | 2,009 | 2,186 | 2,358 | 5,353 | 10,571 |
| TOTAL | $3,361 | $4,386 | $3,201 | $7,317 | $15,331 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 0 | 529 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 1,311 | 1,311 | 1,311 | 0 | 79 |
| TOTAL | $1,311 | $1,311 | $1,311 | $N/A | $79 |
| Total Liabilities | $4,672 | $5,697 | $4,512 | $7,317 | $15,410 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 5,492 | 5,430 | 3,732 | 1,099 | 1,059 |
| Common Shares | 6 | 4 | 3 | 1 | 21 |
| Retained earnings | -321,042 | -308,083 | -293,796 | -181,134 | -144,007 |
| Other shareholders' equity | -10,627 | -10,611 | -10,623 | -10,359 | -10,037 |
| TOTAL | $19,308 | $16,954 | $25,644 | $49,507 | $77,395 |
| Total Liabilities And Equity | $23,980 | $22,650 | $30,156 | $56,824 | $92,805 |